Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MYGN NASDAQ:RIGL NASDAQ:SPPI NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMYGNMyriad Genetics$7.24-5.7%$5.58$3.76▼$29.30$714.58M1.931.31 million shs2.00 million shsRIGLRigel Pharmaceuticals$37.96+0.4%$30.15$13.01▼$43.72$678.39M1.27749,294 shs379,731 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AVSTMVerastem$9.72+4.0%$7.25$2.54▼$11.24$575.45M0.932.55 million shs1.77 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMYGNMyriad Genetics+11.30%+13.11%+27.36%+52.68%-70.78%RIGLRigel Pharmaceuticals+3.67%-5.76%+9.56%+84.31%+191.60%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VSTMVerastem-5.36%-11.46%+13.89%+66.96%+233.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMYGNMyriad Genetics$7.24-5.7%$5.58$3.76▼$29.30$714.58M1.931.31 million shs2.00 million shsRIGLRigel Pharmaceuticals$37.96+0.4%$30.15$13.01▼$43.72$678.39M1.27749,294 shs379,731 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AVSTMVerastem$9.72+4.0%$7.25$2.54▼$11.24$575.45M0.932.55 million shs1.77 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMYGNMyriad Genetics+11.30%+13.11%+27.36%+52.68%-70.78%RIGLRigel Pharmaceuticals+3.67%-5.76%+9.56%+84.31%+191.60%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VSTMVerastem-5.36%-11.46%+13.89%+66.96%+233.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMYGNMyriad Genetics 2.21Hold$12.4572.02% UpsideRIGLRigel Pharmaceuticals 2.40Hold$38.200.63% UpsideSPPISpectrum Pharmaceuticals 0.00N/AN/AN/AVSTMVerastem 3.00Buy$13.2936.68% UpsideCurrent Analyst Ratings BreakdownLatest SPPI, MYGN, RIGL, and VSTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025VSTMVerastemBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/25/2025VSTMVerastemB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/12/2025VSTMVerastemZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/8/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $13.008/6/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $32.006/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMYGNMyriad Genetics$837.60M0.80$0.94 per share7.69$7.70 per share0.94RIGLRigel Pharmaceuticals$179.28M3.80$1.08 per share35.06$0.19 per share199.79SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87VSTMVerastem$10K59,816.88N/AN/A($0.65) per share-14.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMYGNMyriad Genetics-$127.30M-$4.28N/AN/AN/A-47.45%-5.17%-3.44%11/6/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$5.417.0236.15N/A36.51%438.89%57.03%11/6/2025 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AVSTMVerastem-$130.64M-$3.28N/AN/AN/AN/A-2,003.62%-119.85%11/5/2025 (Estimated)Latest SPPI, MYGN, RIGL, and VSTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025VSTMVerastem-$0.64-$0.39+$0.25-$0.39$6.01 million$2.14 million8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMYGNMyriad GeneticsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMYGNMyriad GeneticsN/A1.421.28RIGLRigel Pharmaceuticals0.462.021.90SPPISpectrum PharmaceuticalsN/A2.712.38VSTMVerastem2.063.463.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMYGNMyriad Genetics99.02%RIGLRigel Pharmaceuticals66.23%SPPISpectrum Pharmaceuticals21.67%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipMYGNMyriad Genetics2.40%RIGLRigel Pharmaceuticals9.48%SPPISpectrum Pharmaceuticals2.70%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMYGNMyriad Genetics2,70093.04 million90.81 millionOptionableRIGLRigel Pharmaceuticals16017.94 million16.24 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableVSTMVerastem5061.54 million60.25 millionOptionableSPPI, MYGN, RIGL, and VSTM HeadlinesRecent News About These CompaniesVerastem (NASDAQ:VSTM) Trading Down 7.6% - Should You Sell?September 12 at 2:21 PM | marketbeat.comBTIG Research Reaffirms Buy Rating for Verastem (NASDAQ:VSTM)September 11 at 8:13 AM | marketbeat.comOctagon Capital Advisors LP Invests $10.37 Million in Verastem, Inc. $VSTMSeptember 11 at 6:03 AM | marketbeat.comVerastem (NASDAQ:VSTM) Earns "Buy" Rating from BTIG ResearchSeptember 11 at 2:04 AM | americanbankingnews.comVerastem’s Promising KRAS G12D Inhibitor VS-7375: A Buy Rating Backed by Strong Clinical Data and Strategic OutlookSeptember 9 at 6:30 AM | tipranks.comPolar Asset Management Partners Inc. Invests $300,000 in Verastem, Inc. $VSTMSeptember 9 at 5:21 AM | marketbeat.comLeerink says competitor data suggest promising view for Revolution’s zoldonrasibSeptember 8, 2025 | msn.comVerastem Updates on Cancer Therapy DevelopmentsSeptember 8, 2025 | tipranks.comNuveen LLC Makes New Investment in Verastem, Inc. $VSTMSeptember 8, 2025 | marketbeat.comNomura Holdings Inc. Invests $1.26 Million in Verastem, Inc. $VSTMSeptember 6, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Hits New 1-Year High - Should You Buy?September 5, 2025 | marketbeat.comNantahala Capital Management LLC Sells 1,454,042 Shares of Verastem, Inc. $VSTMSeptember 3, 2025 | marketbeat.comWellington Management Group LLP Takes Position in Verastem, Inc. $VSTMSeptember 2, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Sets New 1-Year High - What's Next?August 30, 2025 | marketbeat.comB. Riley Upgrades Verastem (NASDAQ:VSTM) to Strong-BuyAugust 29, 2025 | marketbeat.comVerastem Oncology to Present at Upcoming Investor ConferencesAugust 27, 2025 | mms.businesswire.comVerastem, Inc. $VSTM Shares Sold by Stonepine Capital Management LLCAugust 26, 2025 | marketbeat.comVerastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?August 25, 2025 | tipranks.comBalyasny Asset Management L.P. Increases Stake in Verastem IncAugust 20, 2025 | gurufocus.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 18, 2025 | marketbeat.comZacks Research Upgrades Verastem (NASDAQ:VSTM) to "Hold"August 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPPI, MYGN, RIGL, and VSTM Company DescriptionsMyriad Genetics NASDAQ:MYGN$7.24 -0.44 (-5.73%) Closing price 04:00 PM EasternExtended Trading$7.36 +0.13 (+1.73%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Rigel Pharmaceuticals NASDAQ:RIGL$37.96 +0.14 (+0.37%) Closing price 04:00 PM EasternExtended Trading$38.00 +0.04 (+0.11%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Verastem NASDAQ:VSTM$9.72 +0.37 (+3.96%) Closing price 04:00 PM EasternExtended Trading$9.77 +0.05 (+0.50%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
